Compare FLNG & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNG | SNDX |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2019 | 2014 |
| Metric | FLNG | SNDX |
|---|---|---|
| Price | $32.72 | $17.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $23.00 | ★ $38.69 |
| AVG Volume (30 Days) | 434.5K | ★ 1.2M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | ★ 9.40% | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | N/A | $107.19 |
| Revenue Next Year | $2.14 | $41.88 |
| P/E Ratio | $19.72 | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $24.00 | $13.00 |
| 52 Week High | $33.40 | $25.59 |
| Indicator | FLNG | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 35.43 |
| Support Level | $28.72 | $16.93 |
| Resistance Level | $33.22 | $22.40 |
| Average True Range (ATR) | 0.74 | 0.68 |
| MACD | 0.05 | -0.19 |
| Stochastic Oscillator | 98.10 | 11.55 |
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.